Why the study?
Knowledge gaps remain regarding optimal diagnostic approaches, the relationship between iron deficiency and ferroptosis in cardiac tissue, and the efficacy of newer iron formulations.
Does intravenous iron therapy reduce heart failure hospitalizations and improve quality of life in patients with heart failure and iron deficiency?
Design
Review
Key result
Intravenous iron therapy, particularly ferric carboxymaltose, reduces heart failure hospitalizations and improves quality of life and exercise capacity in patients with heart failure.
Authors
Loading...
Supports guideline-directed IV iron use in HF with ID; leaves open optimal dosing and long-term outcomes.
Does intravenous iron therapy reduce heart failure hospitalizations and improve quality of life in patients with heart failure and iron deficiency?
Intravenous ferric carboxymaltose is a guideline-recommended therapy that effectively reduces hospitalizations and improves symptoms in patients with heart failure and iron deficiency.
Tsarouchas et al. (2025) conducted a review in Heart failure. Intravenous iron therapy was evaluated. Intravenous iron therapy, particularly ferric carboxymaltose, reduces heart failure hospitalizations and improves quality of life and exercise capacity in patients with heart failure.